For a new list of recommended reading from our Emerging Scholars Advisory Committee, <<click here>>.

Blumberg Institute Faculty News

Thomas Shenk, Princeton University Emeritus Professor,  joins Blumberg Institute faculty.

Doylestown, Pa., May 6, 2022 – Following is noteworthy news about people working at the Baruch S. Blumberg Institute, which is the research arm of the Hepatitis B Foundation.

Thomas E. Shenk, PhD, has joined the Blumberg Institute’s faculty as Distinguished Professor of Experimental Therapeutics and Translational Medicines. Dr. Shenk is Emeritus James Elkins Professor of Life Sciences in molecular biology at Princeton University. He is the founder of Evrys Bio, a 10-year, on-site member company of the Pennsylvania Biotechnology Center (PABC), which is managed by the Blumberg Institute. Please read more about Evrys Bio here.

Liudi Tang, PhD, a postdoctoral researcher working at Evrys Bio with Dr. Shenk, has joined the Blumberg Institute faculty as an assistant professor of experimental therapeutics and principal Investigator at the Baruch S. Blumberg Institute. Dr. Tang is a virologist with a particular focus on the hepatitis B virus (HBV). He received his PhD in 2019 from Drexel University College of Medicine. Please read more here [link pending].

Chari A. Cohen, DrPH, MPH, senior vice president of the Hepatitis B Foundation and Blumberg Institute professor, will be joining the Governing Board of the International Coalition to Eliminate HBV (ICE-HBV). Dr. Cohen also was appointed as the Inaugural Community Chair of the Sidney Kimmel Cancer Center’s Community Advisory Board. The Kimmel Cancer Center is a unit of Jefferson Health. Please read more about Dr. Cohen here.

Richard G. Pestell, MD, PhD, distinguished professor of translational medical research at the Blumberg Institute, recently was elected by his peers to the Fellowship of the Royal College of Physicians London, which is Britain’s “mark of excellence” for physicians. He was previously elected Fellow of the Royal Society of Medicine (UK). Dr. Pestell is founder and CEO of EcoGenome (the Blumberg Institute is an equity partner), which recently completed a successful seed-funding round for the company. Please read more about Dr. Pestell here.

About the Baruch S. Blumberg Institute   An independent, nonprofit research organization, the Blumberg Institute was launched in 2003 by the Hepatitis B Foundation to advance its research mission. Today, the Institute is one of the nation’s leading centers for translational research, particularly for hepatitis B and liver cancer. The Institute supports drug discovery, biomarker discovery and translational biotechnology around common research themes such as chronic hepatitis, liver disease and liver cancer in an environment conducive to interaction, collaboration and focus. The Blumberg Institute is located in the Pennsylvania Biotechnology Center, which it manages, near Doylestown, Pa. For more, go to www.blumberginstitute.org and follow us on Twitter @BlumbergInstit1.